Shin Nippon Biomedical Laboratories, Ltd.

Informe acción TSE:2395

Capitalización de mercado: JP¥50.2b

Shin Nippon Biomedical Laboratories Dirección

Dirección controles de criterios 2/4

El CEO de Shin Nippon Biomedical Laboratories' es Ryoichi Nagata, nombrado en Jan 1991, tiene una permanencia de 33.42 años. posee directamente un 2.46% de las acciones de la empresa, con un valor de ¥1.43B. La antigüedad media del equipo directivo y de la junta directiva es de 2 años y 9 años, respectivamente.

Información clave

Ryoichi Nagata

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO33.7yrs
Participación del CEO2.5%
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva9.3yrs

Actualizaciones recientes de la dirección

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09
Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06
Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12
Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10
Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12
Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

CEO

Ryoichi Nagata (66 yo)

33.7yrs

Permanencia

JP¥144,061,000

Compensación

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer and Group Financial Officer since 2...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Ryoichi Nagata
President33.7yrsJP¥144.06m2.46%
¥ 1.2b
Fumihiko Makino
Senior Executive Officer2.7yrssin datossin datos
Toshiyuki Iwata
Managing Executive Officer and GM of IR Public Relations Department & Sustainability1.7yrssin datossin datos
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director2.3yrssin datossin datos
Kyomi Nagatoshi
Senior Managing Executive Officerno datasin datossin datos
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director20.3yrssin datos0.090%
¥ 45.1m
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Divisionless than a yearsin datossin datos
Hideshi Tsusaki
Senior MD1.7yrssin datossin datos
Terumasa Hirai
Managing Executive Officerno datasin datossin datos
Eishi Tsunozaki
Senior MD & Directorno datasin datos0.043%
¥ 21.8m
Ichiro Nagata
Executive VPno datasin datos40.33%
¥ 20.3b
Takashi Iriyama
Senior Managing Executive Officerno datasin datossin datos

2.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2395 se considera experimentado (2 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Ryoichi Nagata
President41.4yrsJP¥144.06m2.46%
¥ 1.2b
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director14.3yrssin datossin datos
Kyomi Nagatoshi
Senior Managing Executive Officerno datasin datossin datos
Ken Takanashi
Executive VP of Group Corporate Management & Global Business & Director21.8yrssin datos0.090%
¥ 45.1m
Hideshi Tsusaki
Senior MD10.3yrssin datossin datos
Eishi Tsunozaki
Senior MD & Director10.3yrssin datos0.043%
¥ 21.8m
Ichiro Nagata
Executive VP4.3yrssin datos40.33%
¥ 20.3b
Shinichi Fukumoto
Independent Outside Director9.3yrssin datos0.00096%
¥ 482.4k
Takashi Yamashita
Independent Outside Director9.3yrssin datos0.00096%
¥ 482.4k
Masakazu Suda
Full-Time Auditor4.3yrssin datos0.015%
¥ 7.6m
Tsuyoshi Hanada
Independent Outside Director4.3yrssin datos0.0098%
¥ 4.9m
Keiko Totani
Independent Outside Director3.3yrssin datos0.0019%
¥ 964.8k

9.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 2395 se considera experimentada (9 años de antigüedad promedio).